IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 63rd Annual ASH Meeting

Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call on December 11, 2021, at 7:30 p.m. EST. This event follows the oral presentation of clinical data from its Phase 1 study of IGM-2323, a novel IgM antibody for B cell proliferative diseases, at the 63rd ASH Annual Meeting. The call will include IGM's management and Dr. Elizabeth Budde from City of Hope National Medical Center. Attendees can join by phone or via a live webcast on the company's investor website, with a replay available for 90 days.

MOUNTAIN VIEW, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 11, 2021, at 7:30 p.m. EST. The event will take place following an oral presentation featuring clinical data from the Phase 1 dose escalation study evaluating IGM-2323, the Company’s novel CD20 x CD3 T cell engager IgM antibody for the treatment of B cell proliferative diseases, at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

IGM’s management team will be joined by Elizabeth Budde, M.D., Ph.D., Assistant Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center.

The conference call may be accessed by dialing (866) 649-1996 (domestic) or (409) 217-8769 (international) and referring to conference ID 9695193. A live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

What event is IGM Biosciences hosting on December 11, 2021?

IGM Biosciences will host a conference call discussing clinical data from the Phase 1 study of IGM-2323 on December 11, 2021.

Who will present data during the IGM Biosciences conference call?

The conference call will include IGM's management team and Dr. Elizabeth Budde from City of Hope National Medical Center.

How can I access the IGM Biosciences conference call on December 11, 2021?

You can access the call by dialing (866) 649-1996 for domestic or (409) 217-8769 for international calls, using conference ID 9695193.

Where can I find the webcast for the IGM Biosciences conference call?

The live webcast will be available on the 'Events and Presentations' page in the 'Investors' section of IGM Biosciences' website.

How long will the IGM Biosciences webcast be available for replay?

The replay of the webcast will be available for 90 days after the presentation.